Lars Fruergaard Jørgensen, Novo Nordisk CEO (Photographer: Christopher Goodney/Bloomberg via Getty Images)
August 7, 2024 07:13 AM EDT
Pharma
Manufacturing

No­vo Nordisk dou­bles US We­govy pre­scrip­tions as short­ages start to ease, but earn­ings fall be­low ex­pec­ta­tions 

Anna Brown

News Reporter

Near­ly all of No­vo Nordisk’s block­buster GLP-1 We­govy and Ozem­pic drugs have been tak­en off the FDA short­age list as the com­pa­ny re­ports a dou­bling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times